Page last updated: 2024-09-03

safinamide and Parkinson Disease, Secondary

safinamide has been researched along with Parkinson Disease, Secondary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, KZ; Hao, GF; Jin, CF; Wang, ZZ; Xu, TF	1

Other Studies

1 other study(ies) available for safinamide and Parkinson Disease, Secondary

Article	Year
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor. Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Amides; Animals; Benzylamines; Binding Sites; Dopaminergic Neurons; Drug Design; Humans; Male; Mice, Inbred ICR; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Protein Binding; Structure-Activity Relationship	2020

Article

Year

Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.

Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Amides; Animals; Benzylamines; Binding Sites; Dopaminergic Neurons; Drug Design; Humans; Male; Mice, Inbred ICR; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Protein Binding; Structure-Activity Relationship

2020